Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor

Inactive Publication Date: 2020-08-20
BEIJING INCREASE INNOVATIVE DRUG RESEARCH CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a drug that directly reaches the target organ, reducing damage to the whole body and being safer to use. Compared to other dosage forms, the inhalation-type preparation has a faster effect and avoids the need for absorption by the gastrointestinal tract, showing a faster onset of action. The stability of the drug is improved, with various detection indexes not significantly changing after preparation. The added excipients are few in variety, safety is high, the production process is simple, cost is low, and industrial scale production may be realized.

Problems solved by technology

Due to factors such as the dense population, the large number of smoking people and environmental pollution, the morbidity and mortality of respiratory system diseases are high in recent years.
The effect of dextromethorphan is similar to or stronger than codeine, and in June 2005, the U.S. FDA issued an announcement, indicating that improper use of dextromethorphan might cause death or other adverse effects, such as brain damage, loss of consciousness, and arrhythmia.
However, the adverse effects such as a large administered dosage of the oral solution, much hepatic and renal metabolism, a tendency of easily causing damage to organ(s), a relatively small amount of drug reaching the target organ(s), a slow onset of action, and the like are disclosed in publication No.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0071]1000 mL of a solution preparation for aerosol inhalation of carbocisteine was prepared according to the proportion of Prescription 1.

[0072]70% of the total amount of water for injection, which was 700 mL, was added into a liquid preparation apparatus, the water temperature was controlled at 30° C., nitrogen was filled into the water for injection for protection until the liquid preparation was finished, a positive nitrogen pressure was kept in the liquid preparation apparatus, and the next operation was carried out after the residual oxygen content was measured to be 1.6 mg / L.

[0073]Then, 20 mg of disodium edetate (manufactured by Chengdu Huayi Pharmaceutical Excipient Manufacturing Co., Ltd.) was weighed and slowly added into the above water for injection, and the mixture was stirred until the disodium edetate was completely dissolved.

[0074]Next, 4 g of carbocisteine (manufactured by Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd.) was slowly added, and the mixture was stirr...

examples 2 to 13

[0078]A solution preparation for aerosol inhalation of carbocisteine was prepared in the same manner as in Example 1, except that the proportions of Prescriptions 2 to 13 were used in place of that of Prescription 1.

experimental example 1

[0081]The single-dose solution preparations for aerosol inhalation of carbocisteine obtained in Examples 5, 8 and 9 (the solution preparations for aerosol inhalation of carbocisteine were prepared according to the formulas of Prescriptions 5, 8 and 9) were left to stand for one year. The content of carbocisteine in the single-dose solution preparations for aerosol inhalation of carbocisteine obtained in Examples 5, 8 and 9 were determined by the following method for determining the content of carbocisteine after one year, and the color and clarity of the preparations were observed by visual observation. The results were shown in Table 1.

Determination of the Content of Carbocisteine

[0082](1) Octadecylsilane-bonded silica gel was used as a filler (4.6×150 mm, 5 μm), a 20 mM sodium octane sulfonate solution and a 20 mM potassium dihydrogen phosphate solution (pH was adjusted to 2.5 with phosphoric acid) were used as the mobile phase, the detection wavelength was 210 nm, the column temp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present disclosure provides a solution preparation for aerosol inhalation of carbocisteine, and a preparation method therefor. The solution preparation for aerosol inhalation of carbocisteine of the present disclosure comprises carbocisteine, a salt thereof and / or a hydrate thereof, a metal complexing agent, a pH adjusting agent, and water for injection. The solution preparation for aerosol inhalation of carbocisteine of the present disclosure has the characteristics of high efficiency, low toxicity, good stability and high safety, and particularly, greatly reduces the hepatotoxicity and the renal toxicity to patients using the drug.

Description

CROSS-REFERENCE TO EARLIER FILED APPLICATIONS[0001]This application claims the benefit of and is a continuation of PCT / CN2018 / 087527, filed May 18, 2018, which claims the benefit of CN 201711089083.6, filed Nov. 8, 2017, the entire disclosures of which are hereby incorporated by reference.FIELD OF THE INVENTION[0002]The present disclosure belongs to the technical field of pharmaceutical preparation, specifically relates to a solution preparation for aerosol inhalation of carbocisteine and a preparation method therefor.BACKGROUND OF THE INVENTION[0003]Due to factors such as the dense population, the large number of smoking people and environmental pollution, the morbidity and mortality of respiratory system diseases are high in recent years. According to the data of American statistical yearbook, among all categories of causes of death, the ranking of the death caused by respiratory tract-related diseases (excluding tumors) has increased from the 10th in 1970 to the 4th (chronic obst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/12A61K31/198A61P11/08A61K9/00
CPCA61K9/0073A61K9/12A61P11/08A61K31/198A61K9/08A61K47/183A61K47/02A61P11/00A61P11/10A61K9/0078
Inventor ZHANG, BAOXIANHU, JIE
Owner BEIJING INCREASE INNOVATIVE DRUG RESEARCH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products